Literature DB >> 11702866

Vasoactive treatment for hearing preservation in acoustic neuroma surgery.

C Strauss1, B Bischoff, M Neu, M Berg, R Fahlbusch, J Romstöck.   

Abstract

OBJECT: Delayed hearing loss following surgery for acoustic neuroma indicates anatomical and functional preservation of the cochlear nerve and implies that a pathophysiological mechanism is initiated during surgery and continues thereafter. Intraoperative brainstem auditory evoked potentials (BAEPs) typically demonstrate gradual reversible loss of components in these patients.
METHODS: Based on this BAEP pattern, a consecutive series of 41 patients with unilateral acoustic neuromas was recruited into a prospective randomized study to investigate hearing outcomes following the natural postoperative course and recuperation after vasoactive medication. Both groups were comparable in patient age, tumor size, and preoperative hearing level. Twenty patients did not receive postoperative medical treatment. In 70% of these patients anacusis was documented and in 30% hearing was preserved. Twenty-one patients were treated with hydroxyethyl starch and nimodipine for an average of 9 days. In 66.6% of these patients hearing was preserved and in 33.3% anacusis occurred.
CONCLUSIONS: These results are statistically significant (p < 0.05, chi2 = 5.51) and provide evidence that these surgically treated patients suffer from a disturbed microcirculation that causes delayed hearing loss following removal of acoustic neuromas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11702866     DOI: 10.3171/jns.2001.95.5.0771

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  10 in total

Review 1.  Surgery of the ear and the lateral skull base: pitfalls and complications.

Authors:  Bernhard Schick; Julia Dlugaiczyk
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2013-12-13

Review 2.  [Neuroprotective medication in vestibular schwannoma surgery].

Authors:  C Scheller; E Herzfeld; C Strauss
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

Review 3.  Post-operative complications after removal of sporadic vestibular schwannoma via retrosigmoid-suboccipital approach: current diagnosis and management.

Authors:  Stylianos Charalampakis; Dimitrios Koutsimpelas; Haralampos Gouveris; Wolf Mann
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-11       Impact factor: 2.503

4.  Patterns of hearing loss following retrosigmoid excision of unilateral vestibular schwannoma.

Authors:  Melissa J Babbage; Melanie B Feldman; Greg A O'Beirne; Martin R Macfarlane; Philip A Bird
Journal:  J Neurol Surg B Skull Base       Date:  2013-04-01

Review 5.  [Cerebellopontine angle surgery. Part 2: Specific remarks].

Authors:  B Schaller
Journal:  HNO       Date:  2003-03-28       Impact factor: 1.284

Review 6.  Nimodipine in otolaryngology: from past evidence to clinical perspectives.

Authors:  D Monzani; E Genovese; L A Pini; F Di Berardino; M Alicandri Ciufelli; G M Galeazzi; L Presutti
Journal:  Acta Otorhinolaryngol Ital       Date:  2015-06       Impact factor: 2.124

7.  New Treatment in Facial Nerve Palsy Caused by Sagittal Split Ramus Osteotomy of Mandible.

Authors:  Jin Hoon Lee; Kyung Ah Lee
Journal:  Arch Craniofac Surg       Date:  2017-03-25

Review 8.  Nimodipine Reappraised: An Old Drug With a Future.

Authors:  Andrew P Carlson; Daniel Hänggi; Robert L Macdonald; Claude W Shuttleworth
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

9.  Intraoperative Monitoring of the Cochlear Nerve during Neurofibromatosis Type-2 Vestibular Schwannoma Surgery and Description of a "Test Intracochlear Electrode".

Authors:  Anand V Kasbekar; Yu Chuen Tam; Robert P Carlyon; John M Deeks; Neil Donnelly; James Tysome; Richard Mannion; Patrick R Axon
Journal:  J Neurol Surg Rep       Date:  2019-02-04

10.  Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: study protocol of a randomized multi-center phase III trial-AkniPro 2.

Authors:  Christian Scheller; Christian Strauss; Sandra Leisz; Pia Hänel; Ariane Klemm; Simone Kowoll; Iris Böselt; Torsten Rahne; Andreas Wienke
Journal:  Trials       Date:  2021-07-22       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.